CHIKUNGUNYA VIRUS
Clinical trials for CHIKUNGUNYA VIRUS explained in plain language.
Never miss a new study
Get alerted when new CHIKUNGUNYA VIRUS trials appear
Sign up with your email to follow new studies for CHIKUNGUNYA VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chikungunya vaccine enters first human tests
⭐️ VACCINE ⭐️ Not yet recruitingThis early-phase trial tests a new vaccine called PepGNP-ChikV, designed to protect against chikungunya virus. About 40 healthy adults aged 18 to 60 will receive two shots, 42 days apart, and be monitored for safety and immune response for a year. The vaccine uses tiny nanopartic…
Matched conditions: CHIKUNGUNYA VIRUS
Phase: EARLY_PHASE1 • Sponsor: Gylden Pharma Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 12:53 UTC
-
Major trial launches for first chikungunya vaccine
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests an experimental vaccine to prevent chikungunya, a mosquito-borne virus that causes fever and joint pain. About 6,144 adolescents and adults will receive either the vaccine or a placebo. The goal is to see if the vaccine can stop the disease and reduce long-term j…
Matched conditions: CHIKUNGUNYA VIRUS
Phase: PHASE3 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:56 UTC